The latest market report published by Credence Research, Inc. “Global Alzheimer’s Therapeutic Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028″. The Global Alzheimer’s Therapeutic Market generated revenue of around USD 2491.5 million in 2021 and is anticipated to grow a CAGR of over 9.1% during the forecast period from 2022 to 2028 to reach around USD 4201.54 million in 2028. While cumulative growth opportunity presented by the global Alzheimer’s Therapeutic is around USD 1710.04 million from 2022 to 2028.
The global prevalence rate of Alzheimer’s disease is increasing owing to factors such as rising life expectancy, an aging population, and changes in lifestyle, among others. In the coming years, this will propel the Alzheimer’s therapeutics market. According to the World Health Organization (WHO) reports, nearly 50 million people have Alzheimer’s disease in 2021, with nearly 10 million new cases recorded every year. In addition, growing demand for targeted therapies, an increase in R&D activities for the development of novel drugs and therapies, and increased expenditure for the development of healthcare infrastructure are also factors enhancing the growth of the Alzheimer’s Therapeutic market.
According to Alzheimer’s Society, there are no drug treatments that can cure Alzheimer’s disease or any other common type of dementia. However, medicines have been developed for Alzheimer’s disease that can temporarily alleviate symptoms, or slow down their progression, in some cases. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. Based on the drug type, the Alzheimer’s therapeutics market is segmented into:
- Memantine Hydrochloride
- Donepezil Hydrochloride
- Rivastigmine
- Galantamine Hydrobromide
According to press release published by BioArctic Neuroscience AB, the Alzheimer’s disease is age-related and the number of patients doubles every five years beyond age 65, meaning that 30% of 85-year-olds are suffering from the disease. Current estimates indicate 35.6 million people worldwide are affected and researchers estimate that this number could triple by 2050. According to medical practitioners, donepezil, rivastigmine or galantamine is offered as part of treatment for patients with mild-to-moderate Alzheimer’s disease. However, use of memantine is for severe Alzheimer’s disease and most of the medical practitioners recommend memantine for people with moderate Alzheimer’s disease who cannot take the cholinesterase inhibitor drugs. The current market dynamics suggest that drugs currently available in the market are expected to lose their exclusivity during the forecast period.
According to Alzheimer’s Association, if no novel treatments are found to prevent, delay or stop the progression of Alzheimer’s disease, the number of people affected in the U.S. is expected to soar to 15 million by 2050 and the cost of care for Alzheimer’s patients could increase five-fold to $1.2 trillion a year. The drugs currently available in Alzheimer’s therapeutics market treat the cognitive symptoms of the disease such as memory loss, confusion and problems with thinking but do not address the underlying causes of the disease. However, ongoing research on Alzheimer’s treatment is focused on treatments that may restrain or slow down disease progression disease modifying agents. Other areas of research are concentrating at the role inflammation and insulin resistance developed in Alzheimer’s disease.
The global Alzheimer’s Therapeutic market is bifurcated into Drug Name, Drug Class, Distribution Channel, and Geography. Based on drug name, the market is categorized into donepezil, rivastigmine, memantine, galantamine, and manufactured combinations of memantine and donepezil. Based on drug class, the global market is segmented into cholinesterase inhibitors, NMDA receptor antagonists, and manufactured combinations. Based on the distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. On the basis of geography, the market is segmented as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Click here to get the short-term and long-term impact of COVID-19 on this Market: https://www.credenceresearch.com/report/alzeimers-therapeutic-market
Segmentation of Global Alzheimer’s Therapeutic Market –
Global Alzheimer’s Therapeutic Market – By Drug Name
- Donepezil
- Rivastigmine
- Memantine
- Galantamine
- Manufactured Combination of Memantine and Donepezil
Global Alzheimer’s Therapeutic Market – By Drug Class
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Manufactured Combination
Global Alzheimer’s Therapeutic Market – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Why to Buy This Report-
- The report provides a qualitative and quantitative analysis of the global Alzheimer’s Therapeutic market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the previous period from 2016-2020, base year- 2021, and forecast period 2022-2028.
- The report includes information about the competitive landscape, such as how the market’s key players operate at the global, regional, and country levels.
- In-depth analysis of the global market segmentation based on drug name, drug class, distribution channel, and geography.
- The report includes comprehensive and authentic data for all factors such as supply and demand, CAGR, consumer purchasing trends, and several others.
- The global Alzheimer’s Therapeutic market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.
Browse Full Report with Complete ToC: https://www.credenceresearch.com/report/alzeimers-therapeutic-market
Table Of Content:
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation
2. Executive Summary
2.1. Market Snapshot: Global Alzheimer’s Therapeutic Market
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Alzheimer’s Therapeutic Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Major Industry Challenges
3.2.3. Key Growth Pockets
3.3. Attractive Investment Proposition,2021
3.3.1. Drug Class
3.3.2. Distribution Channels
3.3.3. Treatment
3.4. Porter’s Five Forces Analysis
3.4.1. Threat of New Entrants
3.4.2. Bargaining Power of Buyers/Consumers
3.4.3. Bargaining Power of Suppliers
3.4.4. Threat of Substitute Types
3.4.5. Intensity of Competitive Rivalry
3.5. Value Chain Analysis
4. Market Positioning of Key Players, 2021
4.1. Company market share of key players, 2021
4.2. Top 6 Players
4.3. Top 3 Players
4.4. Major Strategies Adopted by Key Players
5. COVID 19 Impact Analysis
5.1. Global Alzheimer’s Therapeutic Market Pre Vs Post COVID 19, 2019 – 2028
5.2. Impact on Import & Export
5.3. Impact on Demand & Supply
6. North America
6.1. North America Alzheimer’s Therapeutic Market, by Country, 2016-2028(US$ Bn)
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. North America Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
6.2.1. Overview
6.2.2. Cholinesterase Inhibitors
6.2.3. NMDA Receptor Antagonists
6.2.4. Others
6.3. North America Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
6.3.1. Overview
6.3.2. Hospital Pharmacy
6.3.3. Retail Pharmacy
6.3.4. Online Pharmacy
6.3.5. Others
6.4. North America Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
6.4.1. Overview
6.4.2. Donepezil
6.4.3. Rivastigmine
6.4.4. Memantine
6.4.5. Galantamine
6.4.6. Manufactured Combination of Memantine and Donepezil
6.4.7. Other
7. Europe
……..
8. Asia Pacific
………..
9. Latin America
……..
10. Middle East
…………
11. Africa
………
12. Global
………..
13. Company Profiles
13.1. AbbVie Inc.
13.2. Lannett Inc.
13.3. Teva Pharma Ltd
13.4. Unichem laboratories Ltd
13.5. Eisai Co. Ltd
13.6. Torrent Pharma Ltd
13.7. Janssen Pharma Inc.
13.8. Cipla Ltd
13.9. Novartis AGNovartis AG
13.10. Lupin Ltd
13.11. Zydus Lifesciences Ltd
13.12. Viatris Inc
13.13. Sun Pharma Industries Ltd
13.14. Macleods Pharma Ltd
13.15. Dr. Reddy’s Laboratories Ltd
13.16. Aurobindo Pharma Ltd
13.17. Amneal Pharmaceuticals Inc.
13.18. Others
……………
Browse Full Report with ToC, List of Figures and List of Tables: https://www.credenceresearch.com/report/alzeimers-therapeutic-market
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, nonlegislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Company Name: Credence Research
Contact Person: Chris Smith
Email: Send Email
Phone: 18003618290
City: SAN JOSE
State: CA
Country: United States
Website: https://www.credenceresearch.com/